What were the main drivers of Medtronic's revenue growth in this quarter?

Revenue growth was primarily driven by strong performance across most business segments, particularly the Cardiovascular Portfolio. This was further boosted by an extra week in the fiscal quarter and favorable foreign currency fluctuations. Key product growth areas included Cardiac Ablation Solutions, Cardiac Pacing Therapies, Defibrillation Solutions within the Cardiovascular segment, and the continued adoption of integrated solutions in the Neuroscience segment.

How did Medtronic's profitability change compared to the prior year?

Medtronic demonstrated improved profitability, with net income attributable to Medtronic increasing to $1.47 billion from $1.04 billion in the prior year's comparable quarter. This resulted in a significant increase in diluted earnings per share (EPS) to $1.14 from $0.81.

What impact did the acquisitions have on the company's financial statements this quarter?

Medtronic completed the acquisitions of Scientia Vascular and SPR Therapeutics during the quarter, which are expected to strengthen its Neuroscience Portfolio. While the financial impact of these acquisitions on the current quarter's results was not individually material, they represent strategic investments for future growth.

What is the current status of the Diabetes Business separation?

Medtronic is progressing with its plan to separate its Diabetes Business. The initial public offering (IPO) of MiniMed Group, Inc. was completed on March 9, 2026. Medtronic retains a controlling financial interest and plans to complete the separation within the fiscal year, intending to divest its remaining interest in MiniMed within fiscal year 2027.

Are there any significant legal matters that could impact Medtronic's financial performance?

Medtronic is involved in several legal matters. Notably, a jury awarded $88 million in damages in a hernia mesh litigation trial, which Medtronic believes is inconsistent with the law and plans to appeal. Additionally, a jury awarded $382 million (which will be trebled) in an antitrust litigation brought by Applied Medical; Medtronic also believes this verdict is inconsistent with the evidence and plans to appeal. In both cases, no liability has been recorded as the ultimate outcome remains uncertain and an estimate of loss is not currently possible.

MDT 10-Q Quarterly Report Q1 FY2027 — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-Q filed September 3, 2026. Cited figures are marked; the original filing is the authoritative source.

Medtronic plc reported a strong fiscal first quarter for 2027, with net sales increasing by 14% to $9.76 billion^a compared to the same period last year.

This growth was driven by robust performance across most business segments, particularly the Cardiovascular Portfolio which saw a 20% increase. The company also benefited from an extra week in the fiscal quarter and favorable foreign currency fluctuations. Diluted earnings per share rose significantly to $1.14^b, up from $0.81 in the prior year, reflecting improved profitability.

The company completed two strategic acquisitions during the quarter: Scientia Vascular and SPR Therapeutics, further strengthening its Neuroscience Portfolio. Management reiterated its confidence in the company's liquidity and financial position, anticipating that existing cash, investments, and credit facilities will adequately cover foreseeable operational needs.

02—Key points

Key Highlights

Net sales increased by 14% to $9.76 billion, driven by broad-based growth across segments.
Cardiovascular Portfolio sales surged by 20%, with Electrophysiology Therapies showing a notable 30% increase.
Diluted earnings per share (EPS) grew to $1.14 from $0.81 year-over-year.
The company completed two strategic acquisitions: Scientia Vascular and SPR Therapeutics, enhancing its Neuroscience offerings.
Operating cash flow significantly increased by 64% to $1.79 billion.
The company is progressing with the planned separation of its Diabetes Business, with MiniMed having completed its IPO.
Despite a jury verdict in the Applied Medical antitrust litigation, the company believes the decision is inconsistent with the evidence and plans to appeal, with no liability recorded yet.

03—Questions

Frequently Asked Questions

What were the main drivers of Medtronic's revenue growth in this quarter?
Revenue growth was primarily driven by strong performance across most business segments, particularly the Cardiovascular Portfolio. This was further boosted by an extra week in the fiscal quarter and favorable foreign currency fluctuations. Key product growth areas included Cardiac Ablation Solutions, Cardiac Pacing Therapies, Defibrillation Solutions within the Cardiovascular segment, and the continued adoption of integrated solutions in the Neuroscience segment.
How did Medtronic's profitability change compared to the prior year?
Medtronic demonstrated improved profitability, with net income attributable to Medtronic increasing to $1.47 billion from $1.04 billion in the prior year's comparable quarter. This resulted in a significant increase in diluted earnings per share (EPS) to $1.14 from $0.81.
What impact did the acquisitions have on the company's financial statements this quarter?
Medtronic completed the acquisitions of Scientia Vascular and SPR Therapeutics during the quarter, which are expected to strengthen its Neuroscience Portfolio. While the financial impact of these acquisitions on the current quarter's results was not individually material, they represent strategic investments for future growth.
What is the current status of the Diabetes Business separation?
Medtronic is progressing with its plan to separate its Diabetes Business. The initial public offering (IPO) of MiniMed Group, Inc. was completed on March 9, 2026. Medtronic retains a controlling financial interest and plans to complete the separation within the fiscal year, intending to divest its remaining interest in MiniMed within fiscal year 2027.
Are there any significant legal matters that could impact Medtronic's financial performance?
Medtronic is involved in several legal matters. Notably, a jury awarded $88 million in damages in a hernia mesh litigation trial, which Medtronic believes is inconsistent with the law and plans to appeal. Additionally, a jury awarded $382 million (which will be trebled) in an antitrust litigation brought by Applied Medical; Medtronic also believes this verdict is inconsistent with the evidence and plans to appeal. In both cases, no liability has been recorded as the ultimate outcome remains uncertain and an estimate of loss is not currently possible.

04—Continue

← View all 10-Q filings